Methods: Analysis of pre-operative characteristics, operative outcome, false lumen thrombosis, aortic diameter and survival.

Results: 58 consecutive patients were included (49

elective, 9 urgent, mean age 66 years). Mean aortic diameter was 6.4 cm (Standard deviation SD 1.3 cm). Three patients died perioperatively (5%, 1 urgent, 2 elective). Complications included retrograde type A dissection (n = 3), paraplegia (1), and transient ischaemic attack (1). Estimated survival (Kaplan-Meier) was 89% (1-year) and 64% (3-years). Forty-seven patients had mid-term imaging follow-up at mean 38 months. Reintervention rate was 15% at 1-year and 29% at 3-years. Aortic diameter decreased in 24, was stable in 15 and increased in 8. Mid-term survival was higher in patients with aortic remodelling (reduction of aortic diameter >0.5 cm; 3-year 89%) www.selleckchem.com/products/cx-4945-silmitasertib.html than without (54%; Log Rank p = 0.005). Remodelling occurred with extensive false lumen thrombosis.

Conclusion: Satisfactory mid-term outcome after TEVAR for CD remains a challenge. Survival is associated with aortic remodelling, which is related to persistence of flow in the false lumen. (C) 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“A 2-D matrix ultrasound array is used to monitor acoustic radiation force impulse

(ARFI) induced shear wave propagation in 3-D in excised canine muscle. From a single acquisition, both the shear wave phase and group velocity can be calculated to estimate the shear wave speed (SWS) along and across the fibers, Natural Product Library as well as the fiber orientation in 3-D. The true fiber orientation found using the 3-D radon transform on B-mode volumes of the muscle was used to verify the fiber direction estimated from shear wave data. For the simplified imaging case when the ARFI push can be oriented perpendicular to the fibers, the error in estimating the fiber orientation using phase and group velocity measurements was 3.5 +/- 2.6 degrees and 3.4 +/- 1.4 degrees (mean +/- FDA-approved Drug Library in vivo standard deviation),

respectively, over six acquisitions in different muscle samples. For the more general case when the push is oblique to the fibers, the angle between the push and the fibers is found using the dominant orientation of the shear wave displacement magnitude. In 30 acquisitions on six different muscle samples with oblique push angles up to 40, the error in the estimated fiber orientation using phase and group velocity measurements was 5.4 +/- 2.9 degrees and 5.3 +/- 3.2 degrees, respectively, after estimating and accounting for the additional unknown push angle. Either the phase or group velocity measurements can be used to estimate fiber orientation and SWS along and across the fibers. Although it is possible to perform these measurements when the push is not perpendicular to the fibers, highly oblique push angles induce lower shear wave amplitudes which can cause inaccurate SWS measurements.